Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant

• DOI: 10.1016/j.xcrm.2022.100679
• Publication Date: 2022-06-20T08:23:23Z
• Authors: Kirsten E. Lyke; Robert L. Atmar; Clara Dominguez I...; Christine M. Posavad; Daniel Szydlo; Rahul Paul Chourd...; Meagan E. Deming; Amanda Eaton; Lisa A. Jackson; Angela R. Branche; Hana M. El Sahly; Christina A. Rostad; Judith M. Martin; Christine Johnston; Richard E. Rupp; Mark J. Mulligan; Rebecca C. Brady; Robert W. Frenck; Martín Bäcker; Angelica C. Kottkamp; Tara M. Babu; Kumaravel Rajakumar; Srilatha Edupuganti; David Dobrzynski; Rhea N. Coler; Janet I. Archer; Sonja Crandon; Jillian A. Zemanek; Elizabeth R. Brown; Kathleen M. Neuzil; David S. Stephens; Diane J. Post; Seema U. Nayak; Mehul S. Suthar; Paul C. Roberts; John H. Beigel; David C. Montefiori; Jennifer S. Husson; Angie Price; Jennifer A. Whitaker; Wendy A. Keitel; Ann R. Falsey; Ian Shannon; Daniel Graciaa; Nadine Rouphael; Evan J. Anderson; Satoshi Kamidani; Gysella B. Muniz; Sonika Bhatnagar; Anna Wald; Megan Berman; Laura Porterfield; Amber Stanford; Jennifer Lee Dong; Steven E. Carsons; Diana Badillo; Susan Parker; Michelle Dickey; Sasha E. Larsen; John Hural; Brian Ingersoll; Marina Lee; Lilin Lai; Katharine Floyd; Madison Ellis; Kathryn M. Moore; Kelly Manning; Stephanie L. Foster; Mit Patel
• Keywords: Heterologous; Boosting; Antibody titer

The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibits reduced susceptibility to vaccine-induced neutralizing antibodies, requiring a boost generate protective immunity. We assess the magnitude and short-term durability antibodies after homologous heterologous boosting with mRNA Ad26.COV2.S vaccines. All prime-boost combinations substantially increase neutralization titers Omicron, although boosted decline rapidly within months from peak response compared against prototypic D614G variant. Boosted are higher for vaccine boosting, boosting. Homologous generates nearly equivalent activity sublineages BA.1, BA.2, BA.3 but modestly BA.2.12.1 BA.4/BA.5 BA.1. These results have implications requirements protect future variants SARS-CoV-2. This trial was conducted under ClincalTrials.gov: NCT04889209.